secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0000950170-25-048586
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics shareholders approve 1:40 reverse stock split; effective April 11, 2025
--------------------------------------------------------------------------------

- At special meeting March 31, 2025, shareholders approved reverse split (1:20 to 1:50 range) - 30.7M for, 201k against.
- Board set final ratio at 1:40; effective 12:01 a.m. ET April 11, 2025; trading symbol remains HCWB.
- Shareholders also approved ELOC with Square Gate Capital Master Fund and conversion of up to $6.905M of senior secured notes.
- Note conversion proposal had 19.1M abstentions, suggesting possible insider conflict; approved with 7.8M for.
- Reverse split aims to regain Nasdaq listing compliance; new CUSIP 40423R204.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025048586/0000950170-25-048586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025048586/hcwb-20250401.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-048586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer